United States· US:0169-3205_133d5f6e-b40f-47b6-ab47-10dc37114d79
Fiasp
A medicinal product containing insulin aspart, registered in United States by Novo Nordisk.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- INSULIN ASPART
- Manufacturer
- Novo Nordisk
- Country
- United States (US)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 4
- ndc1101693205155 CARTRIDGE in 1 CARTON (0169-3205-15) / 3 mL in 1 CARTRIDGE (0169-3205-11)
- ndc1101693205955 CARTRIDGE in 1 CARTON (0169-3205-95) / 3 mL in 1 CARTRIDGE (0169-3205-91)
- ndc110169-3205-15
- ndc110169-3205-95
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Insulin aspart in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsKirsty 100 IE/ml, oplossing voor injectieBiosimilar Collaborations Ireland Limited
- CzechiaDAZPARDAGan & Lee Pharmaceuticals Europe GmbH, Düsseldorf
- United KingdomFiasp 100units/ml solution for injection 10ml vialsNovo Nordisk Ltd
- BelgiumDazparda 100 U/mlGan & Lee Pharmaceuticals Europe
- FinlandDazpardaGan & Lee Pharmaceuticals Europe GmbH
- SwedenDazparda 100 E/ml Injektionsvätska, lösning i förfylld injektionspennaGan & Lee Pharmaceuticals Europe GmbH
- IcelandFiaspNovo Nordisk A/S*
- PolandDazpardaGan & Lee Pharmaceuticals Europe GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Dazparda, Fiasp
- Liechtenstein · Dazparda, Insulin Aspart Sanofi
- Norway · Dazparda, Fiasp
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c8df6ba8-b991-46aa-9cb3-bc4627bd8c6f GET /v1/drugs/c8df6ba8-b991-46aa-9cb3-bc4627bd8c6f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "SUBCUTANEOUS",
"source": "ndc",
"strength": "100",
"substance": "INSULIN ASPART",
"productndc": "0169-3205",
"dosage_form": "INJECTION, SOLUTION",
"dea_schedule": null,
"strength_unit": "[iU]/mL",
"application_number": "BLA208751",
"marketing_category": "BLA"
}See everything about insulin aspart.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.